Home Factor company Juva Life Announces Flōs, a New Line of Branded Cannabis Flower Products

Juva Life Announces Flōs, a New Line of Branded Cannabis Flower Products

0

Juva Life Inc.

New line of branded cannabis products diversifies company’s product offerings; Complete pharmaceutical research

VANCOUVER, British Columbia, Sept. 21, 2022 (GLOBE NEWSWIRE) — Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life”, “Juva” or the “Company”) , a life sciences company with pharmaceutical research and development and consumer cannabis production and distribution, today announced the launch of the company’s new product line, Flōs, a brand line of flower and pre-rolled cannabis products.

“Our Flōs line provides consumers with high-quality cannabis products without paying the highest prices, and further expands our product category to capitalize on the massive market growth in California,” said Doug Chloupek, CEO and founder of Juva. “We are delighted that the completion of construction of our Stockton cultivation facility has doubled our production capacity, enabling us to offer new consumer packaged products that our customers demand.”

Flōs is the Latin word for flower or bloom, and the unique beauty of the cannabis flower is on full display with Juva’s new product line. With eight-ounce quantities, pre-rolls in one-gram quantities, and half-ounce florals, these meticulously selected cultivars are economical without sacrificing quality.

The Flōs line of flowers is available for distribution statewide in California, and is also available through Juva Delivery, which is a vertically integrated division of Juva Life, Inc.. Juva Delivery also offers contactless prepayment options through Paytender, a secure, free online payment service. The Flōs line of flowers will also be featured in the future at the company’s upcoming retail store, which has been approved for licensing by the City of Redwood City and is currently under construction.

Every Flōs product starts with the highest quality cannabis cultivars grown in the company’s 30,000 square foot cannabis cultivation facility in Stockton, California. Once harvested and dried, the material is then transferred to Juva’s distribution division for final processing and distribution throughout the state. To find locally available products in the San Francisco Peninsula area, visit here.

ON BEHALF OF COUNCIL,

-Doug Chloupek-

Doug Chloupek, CEO and Founder

Juva Life Inc.

[email protected]

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (ENG: 4VV)

Juva Life uses cutting-edge science to discover, develop and market safe and effective pharmaceutical and wellness products, both in the cannabis consumer segment and in the non-cannabinoid medical industry. The company is successfully executing on its 2018 roadmap, initially starting with the standardization of cultivation, extraction and formulation to deliver repeatable benefits to consumers. Juva is building on these skills in natural product process chemistry, to now include discovery pharmacology. The Company will leverage revenues from its retail operations to advance its clinical development and consumer efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with important applications in consumer products and pharmaceuticals. Juva strives to challenge the cannabis market with the industry’s investment-grade, next-generation business model. Learn more about: https://juvalife.com/.

For more information, please contact:

Juva Life Investor Relations

Such : +1 833-333-5882 (JUVA)

E-mail: [email protected]

Forward-looking statement

This press release contains statements and information which, to the extent that they are not historical facts, may constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking information may include financial and other projections, as well as statements regarding future economic plans, objectives or performance, or assumptions underlying any of the foregoing. In some instances, forward-looking statements may be identified by words such as “may”, “would”, “could”, “will”, “likely”, “unless”, “anticipate”, “believe”, “have the ‘intention’, ‘plan’, ‘forecast’, ‘project’, ‘estimate’, ‘prospect’, or their negative form or other similar expressions relating to matters which are not historical facts. Examples of such statements include, but are not limited to, statements regarding the Company’s objectives and business plans; product development, marketing strategy and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the information. forward-looking, including, without limitation, risks related to the Company’s future business plans; the risks that the Company may not be able to retain its key personnel; the risks that the Company may not be able to obtain financing on reasonable terms or at all, as well as all other risks described in the Company’s management report for the financial year ended December 31, 2020 under the section “Risks and uncertainties”. Accordingly, readers should not place undue reliance on such forward-looking information. Further, any forward-looking information speaks only as of the date such statement is made. New factors emerge from time to time, and it is not possible for the management of the Company to foresee all of these factors and assess in advance the impact of each of these factors on the Company’s business or the extent to which any factor, or combination of factors, could cause actual results to differ materially from those contained in the forward-looking information. The Company undertakes no obligation to update forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unforeseen events, except as required by law, including securities laws.

CSE does not accept responsibility for the adequacy or accuracy of this release.